Transition-ready technologies and expertise from the Chemical and Biological National Security Program at LLNL
HSARPA has initiated a new Bioinformatics and Assay Development solicitation, BIAD2 (BAA 06-01), to address a number of technology gaps and requirements for biodetection (www.hsarpabaa.com). This solicitation will leverage the vast research and development capabilities of the private sector and academia in order to meet the needs of HSARPA and Homeland Security. In order to meet these requirements, this solicitation will: (1) Develop and validate actionable assays for the public and private sector; (2) Develop and validate new assays and novel assay methodologies to enhance existing detection systems and enable future detection platforms; (3) Develop next generation assays which are robust against novel, emerging and engineered threats; (4) Develop novel assays that detect low levels of ribonucleic acid (RNA)-based viral threats in complex backgrounds; (5) Develop novel assays to characterize the viability, degree of virulence or toxicity, and countermeasure resistance of a biological agent; and (6) Develop new bioinformatics tools to support assay development and assay validation The Lawrence Livermore National Laboratory (LLNL) Bioassays and Signature Program (BSP) develops nationally-validated detection and identification assays to cover the full range of biological threat agents, starting from human, animal, and plant pathogens on the Select Agent list. The assays that have been co-developed by the CDC and the BSP are used internationally and represent the gold standard for molecular detection of select agent pathogens for the public health community. They are also used in the DHS environmental monitoring operations such as BioWatch and DHS National Security Special Events support. These reagents have been used to process and analyze more than 5 million samples and have delivered exceptional performance for the end users, with zero false positives since their deployment. Currently, highly-multiplexed nucleic acid assays that represent the ''next-generation'' in BioWatch assays have been developed at LLNL and are in final evaluation at CDC. LLNL is a full partner to the LRN network, as well as a formal LRN member, sanctioned to perform these diagnostics on field samples. The Program has assay extensive experience developing, testing, validating, deploying, and commercializing biodetection assays and instrumentation. The following pages contain additional descriptions of our Program's capabilities. We have a demonstrated track record of established collaborations and look forward to partnering with offerers to the HSARPA BAA to continue to meet the national needs and requirements.
- Research Organization:
- Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)
- Sponsoring Organization:
- USDOE
- DOE Contract Number:
- W-7405-ENG-48
- OSTI ID:
- 898510
- Report Number(s):
- UCRL-TR-219363; TRN: US200708%%117
- Country of Publication:
- United States
- Language:
- English
Similar Records
The Autonomous Pathogen Detection System (APDS)
Novel Agents for Gram-Negative Biodefense Pathogens Final Report CRADA No. TC02128.0